{"name":"Verona Pharma","slug":"verona","ticker":"VRNA","exchange":"NASDAQ","domain":"vfrpharma.com","description":"Verona Pharma is a biopharmaceutical company focused on developing treatments for respiratory diseases. The company's lead product, ensifentrine, is being developed for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Verona Pharma is a relatively small company with a limited product portfolio, but it has shown promise in its clinical trials. The company's pipeline is focused on respiratory diseases, with a focus on COPD and asthma.","hq":"London, UK / Raleigh, NC","founded":0,"employees":"","ceo":"David Zaccardelli","sector":"Respiratory / Specialty Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$6.5B","metrics":{"revenue":42279000,"revenueGrowth":0,"grossMargin":0,"rdSpend":44574000,"netIncome":-173418000,"cash":474242000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Ohtuvayre first approved","drug":"Ohtuvayre","drugSlug":"ensifentrine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Ensifentrine patent cliff ($0.0B at risk)","drug":"Ensifentrine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ensifentrine Dose 1","genericName":"Ensifentrine Dose 1","slug":"ensifentrine-dose-1","indication":"Cystic fibrosis","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ohtuvayre","genericName":"ENSIFENTRINE","slug":"ensifentrine","indication":"chronic obstructive pulmonary disease (COPD)","status":"marketed"}]}],"pipeline":[{"name":"Ensifentrine Dose 1","genericName":"Ensifentrine Dose 1","slug":"ensifentrine-dose-1","phase":"phase_2","mechanism":"Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC).","indications":["Cystic fibrosis"],"catalyst":""},{"name":"Ohtuvayre","genericName":"ENSIFENTRINE","slug":"ensifentrine","phase":"marketed","mechanism":"Ohtuvayre works by blocking an enzyme called phosphodiesterase 3, which helps to increase the levels of a molecule called cyclic AMP in the lungs.","indications":["chronic obstructive pulmonary disease (COPD)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Verona Pharma reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Verona Pharma Announces Collaboration with University of California, San Francisco","summary":"Verona Pharma announced a collaboration with the University of California, San Francisco to develop new treatments for respiratory diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-31","type":"trial","headline":"Verona Pharma Announces Top-Line Results from Phase 3 Trial of Ensifentrine in COPD","summary":"Verona Pharma announced top-line results from a Phase 3 trial of ensifentrine in COPD, showing significant improvements in lung function.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPbGhmZnM5LUI3eVktOWt0eXRia0k3bkd5cW1PMGJqdFQzS3dhenV2MHM5dVJBbXVVMUxtWU5BT3hLeUdYMUFuRUtkRDZkRU9OMVpjUGFwT3lnaVlBbnJBVGVkUkFPTXpQTVl5VWFPc1RMUEUxQjZKZkkyOHRsbXRIRmpkLVZwQTJH?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend - Yahoo Finance","headline":"Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Tradi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQcHExN0RmSlZWUDY0aXhma3I4aXpYOWRBWEJta3pSR19HMGlHTUE3WnBNNkphTEJRUWFBNGZBQzYtd0h0ZjNFQ2VLS21HVDRCbDVkSm1BQVB2QkV5bjgyTllERnhHbjJ5blVOQ19lMGpFbHBTUGNuY0ktYV9TVTZ5NU1Zck9qTmxheHJJRVRpOFJyZWhaY0Fma1lMYVBVUGdrTnh4QV9pdjdNbEYzTGVxY0cyWnRUYTcxOXp0c1BBT2xnTEtPcllwQ0dDUzFhQQ?oc=5","date":"2025-10-07","type":"pipeline","source":"Investing.com","summary":"Merck completes acquisition of Verona Pharma; VRNA shares delisted from Nasdaq - Investing.com","headline":"Merck completes acquisition of Verona Pharma; VRNA shares delisted from Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPZUNHQS01WEpQaEJEZHFRUXB0UHNsOXM5ejRZRTI5TVJWSFRXaFVmQjNXbVdUTlJaMlVNdlN1ZkRTSk12RnYzQkY1NjNpOG40WTN6RkRBdlgzV2laR3FoVnhoS0NyY3RCc0dxRmJIb0lpNDBrYTNoMjBkNVppUDV2NWNNYzR0Q1ZmMDROMXZ0Nk1veHpSNXVGMG9pRVVQYnNEUGRIY3FHUXhpUS1ySFFCcG13?oc=5","date":"2025-10-07","type":"pipeline","source":"Investing.com","summary":"Merck completes $10 billion acquisition of Verona Pharma - Investing.com","headline":"Merck completes $10 billion acquisition of Verona Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQMlIyT2g0UXlhWlN6ZzlUYnk4QnVDMjBFd1g5bXRyVExSb3RkdDJxc1k1MUYxTFNZSFNkYjNrWm81OGJ5dkNXN2hybW5qUlZoaU13MFVYcTNzMlRUS2J6SnBiRTlVZ0xXMGVma2NvVjZoNnp2NEl2WVVteXN3RjdOb1d4Y0VoS1VzbERlQmdXcW4?oc=5","date":"2025-10-07","type":"pipeline","source":"Yahoo Finance","summary":"Merck Completes Acquisition of Verona Pharma - Yahoo Finance","headline":"Merck Completes Acquisition of Verona Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBFV0kxOFBqMnVHeWVET3ltRTFmTVhSOVkzSl9HYjhuT0VGaE50bmF6R3EtRlJmTS1yOEJKV0h4OG1TWGRINm9Xd0VHMXV2Z3pNVEx3OFJuTnJ5S2I5Z1lsX1I4R0RRM2VJMFB1Y3drLXhsSk9FWlpoYzFwZ2VZUlE?oc=5","date":"2025-09-30","type":"deal","source":"Yahoo Finance","summary":"Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio - Yahoo Finance","headline":"Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQNThsZXBCNXlpX3ZheWdwVWF5Q3RvM1VaNHhtY1VFMG1BYmNnbE1LM1h1MU9jZ0dBU3dIZFBHWTB1S2QwRkFYRDUwS21JN2IyVUpYMl8yLWF2d2RTUVNzR3hkbXpkQ3VZbUM2MGdrZGwzMjBYdEdocVpSX0w4UzlsY2F4NVFOZWFrd014OUFEOUNEUkxFUTFOYl9wdVVRZmRtdmxFeUlKOUlrLXRzRTZjWER3akdNSVE?oc=5","date":"2025-09-24","type":"regulatory","source":"Stock Titan","summary":"$10 Billion Respiratory Disease Deal: Merck to Acquire Verona Pharma After 99.5% Shareholder Approval - Stock Titan","headline":"$10 Billion Respiratory Disease Deal: Merck to Acquire Verona Pharma After 99.5% Shareholder Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOUlJMLXFVM0EtX2xKY0R0LVBoS2c1eHF1MVIzR3JQSTdpU0kzakh2eU9XRVNFd2QtN2gxaUtpZkVMWGw0d3BKak5oZFJoNS1sVFY0aEVWZGZHM1hBQndOV3BnckhCUVIxMVZEVVh2dWpXVWFqM3VCaF84RzFyVEt5anNNM3R6NEN2NzRYSU05MDJMS083YTlR?oc=5","date":"2025-07-13","type":"pipeline","source":"Quiver Quantitative","summary":"Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative","headline":"Verona Pharma (VRNA) Opinions on Merck Acquisition News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNbkVic0FZdFAtV2NMLW5qVFl2WDNPQ0dEYXk0ZWtNcmtpV1hMTHEyVFFzazIzVXNwOVczZWR5RmlmazlwYUpWdWRjNW0tMVpjNGwxR3p6T0NDY01fNVJrODdtdlk2LTkwVVlSMWVIS1B1cWpCNjJKRTFXNTVKTkhiS3FWbVA?oc=5","date":"2025-07-10","type":"deal","source":"Yahoo Finance","summary":"Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck - Yahoo Finance","headline":"Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gJBVV95cUxNMGhDd29NTnVMLW9zR1pDVTJGamp2M3ZUN2NCX0NNTTA4dVlSU1d5aHpvbTRZSm4yX24xeVNkelMzN1lkeks4Z1Z6SzN3bmlPMjhxWmJRU09FVEVZbDhwWi1xSklmNlJ2VXFtNnhZTVR3U1NLSFl6dmtnZExLZi1oODZTSE5pMGM3WUltaVFaOUJXTzBTdG9TRWl0SUM1dy1SeFFzVnB3ZjAwcWtndzU1UDQ0SThnNzlES0FWU2dDczAxaW4ta2UzQVJ5R0dja0NkODM4aDVoWTVicC1ocm14LUYzVDFsM2lxdnhzZFIzYm03enpyQlpUQ0FlbG5hQjdZY0h0ZFhQbGg0eW9IMHJzb282V0o2UWhXeVpnTmVoRmpnYWtsQlUzMW13LVdTSEU0MVJOeF9iaGNrZDRGZEozWHNtMUxnMkxOLUdYelk2UGhoZVJrSFhFZE5jeWVWbERrSkRNRVg4dmk1UQ?oc=5","date":"2025-07-09","type":"deal","source":"Business Wire","summary":"Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade -","headline":"Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Main","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBOd21hMmpzM3F6enJIR0tyTE5pWThQQng5WHlBWGRpeXdHZDY2UFk3b2loOVRjSmxxeWJZdHlfbFlzSjRaTEVncTJQTnV0Zkp6RTBMVkU0SWhxdXJyQlFsbG52TWoxS3lMZ1QxRWJ1eDRCLUpOQVHSAXtBVV95cUxOUTNqMlZqZkxtczVsU21FeHEtdUdZNl85bFhCUWN5Si03UkdvWWRiSUowaS1NRFhFV2FmMlFkTk9hWjZDSnpMZEZhS3lrNlRrWmRnU1BBNmdfQnBtVkloYkpISHRDVldrTXY4R196WmZpdnZXczBaRmVkRHc?oc=5","date":"2025-07-09","type":"pipeline","source":"cnbc.com","summary":"Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda - cnbc.com","headline":"Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBuMnJPZ3J6N2VkN0dsOWhvRTVFZGh5aXlBNjAwdm42UGt5V19oUWhLX2JpMHNodnlzSGhtdzBmWFBFVEFpZVFCMy16bjF6WE4wa3JUZnJrejU3c2pyQ0E2TWdPOEo4al9xTkUwbGJ1ekF1NXc3TWpHQVZHUQ?oc=5","date":"2025-07-09","type":"deal","source":"Investor's Business Daily","summary":"Merck Snags A $10 Billion Buyout - Investor's Business Daily","headline":"Merck Snags A $10 Billion Buyout - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQcGR3UHd1R0NvY2dRWVJmU1VBODZzMXVZNkpHcU1ZLUFaVHJBc2Y5NGZvaVBSOVlDdUlwV3FGU0F3bTRtMWRJM3pTN3otSk1odlNucGlNRWxLWjQ0NkJ0aTU0UHotbjRQYVlWOV94S2JOVFZ1UXBTaEYzN2RKbVJGc00yR0RKVy04bnBTcGMyTk8zMlF2bXNXcHBlcTUwYS1EaFlpZTVFSmhjNW83NV9r?oc=5","date":"2025-07-09","type":"deal","source":"Investopedia","summary":"Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B - Investopedia","headline":"Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B","sentiment":"neutral"}],"patents":[{"drugName":"Ensifentrine","drugSlug":"ensifentrine","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["GSK","AstraZeneca","Biogen"],"therapeuticFocus":["Respiratory","COPD","Asthma"],"financials":{"source":"sec_edgar","revenue":42279000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":42279000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2023-12-31"},{"value":458000,"period":"2022-12-31"},{"value":458000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":44574000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-173418000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":474242000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}